Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2022

Login to access report north_east
Contact sales account_box

characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation 
predominant, diarrhea predominant, and mixed; this analysis focuses on IBS-D, the diarrhea-predominant subtype. Limited treatment options are available for 
IBS, and only a few drugs have secured FDA approval for IBS-D. Current prescribing among recently treated and newly diagnosed IBS-D patients?
 * How have Viberzi and Lotronex been integrated into the treatment algorithm, and what are their sources of business?
 * What percentage of IBS-D patients receive drug therapy within 365 days
*Markets covered:* United States
*Key companies:* AbbVie, Salix, Sebela Pharmaceuticals
*Key drugs:* Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulphate / scopolamine, SSRIs, SNRIs, tricyclic agents, diphenoxylate
characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation 
predominant, diarrhea predominant, and mixed; this analysis focuses on IBS-D, the diarrhea-predominant subtype. Limited treatment options are available for 
IBS, and only a few drugs have secured FDA approval for IBS-D. Current    prescribing among recently treated and newly diagnosed IBS-D patients?
 * How have Viberzi and Lotronex been integrated into the treatment algorithm, and what are their sources of business?
 * What percentage of IBS-D patients receive drug therapy within 365 days
*Markets covered:* United States
*Key companies:* AbbVie, Salix, Sebela Pharmaceuticals
*Key drugs:* Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulphate / scopolamine, SSRIs, SNRIs, tricyclic agents, diphenoxylate
 

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Multiple Myeloma – Current Treatment – Current Treatment: Physician Insights – Multiple Myeloma (US)
Multiple myeloma represents a complex and increasingly competitive hematologic malignancy landscape, with treatment approaches evolving rapidly across lines of therapy. While IMiDs, proteasome…
north_east
Report
Multiple Myeloma – Current Treatment – Treatment Sequencing – Multiple Myeloma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…
north_east
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
north_east
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east